Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMIRNATY in adults with long COVID
2021-003331-28Phase 4Active
- Sponsor
- Felix Gutierrez Rodero
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-COVID syndrome comparing COMIRNATY with Placebo (2 arms). Primary endpoint: Change in global COVID-19 Symptom Questionnaire score at week 12. Started Jun 2021; status: active.
02
Drugs
tozinameran
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2021-003331-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003331-28.